Syschem (India) Limited (531173) Fair Value & Analysis

Healthcare · IN · Market cap ₹126M

Below-average quality, and screening another 79% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹8.00). The favourable scenario is already priced in.
• Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹6.11 – ₹71.11 · fair‑value band ₹4.80 – ₹8.00 · the ₹31.07 price screens above the ₹6.40 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Syschem (India) Limited (531173) currently trades at ₹31.07, while our model-based Fair Value estimate is ₹6.40, implying the stock looks roughly 79.4% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Syschem (India) Limited generated revenue of ₹717M at a net margin of -4.9%. Revenue declined 32.8% year over year. Net debt stands at ₹3.5M. The stock trades on a trailing P/E of 60.8 (as of Jul 4, 2026). Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹4.80 (bear case) to ₹8.00 (bull case); at ₹31.07, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside, at -79%, 531173 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹235.73) versus Asset-Based (₹38.08). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Syschem (India) Limited manufactures and sells active pharmaceuticals ingredients (APIs), intermediates, bulk drugs, and specialty chemicals in India. Its APIs/intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, cefixime, and cefadroxil.

Full company description

Syschem (India) Limited manufactures and sells active pharmaceuticals ingredients (APIs), intermediates, bulk drugs, and specialty chemicals in India. Its APIs/intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, cefixime, and cefadroxil. The company also offers generic products in tablet, softgel/capsule, injection, syrup/suspension, and herbal and personal care forms. In addition, it engages in the distillation of specialty solvents, such as DMF, acetonitrile, ethyl acetate, and THF; and contract manufacturing business. The company was incorporated in 1993 and is based in Chandigarh, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Syschem (India) Limited reported revenue of ₹6.5B in FY2026 versus ₹656M in FY2022, a compound +77.7%/yr. Reported net income was ₹109M in FY2026.

531173 screens 79% overvalued. Compare with AstraZeneca Pharma India Limited →

Peer Group

Health Care · 2285 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)

Valuation Multiples vs Health Care median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.